Final Phase 2B Results with AEF0117 in Cannabis Use Disorder (CUD)

Aelis Farma announces the positive results of its clinical Phase 1/2 Study with AEF0217 in young adults with Down syndrome

Results of the clinical Phase 2B Study with AEF0117 in Cannabis Use Disorder

Aelis Farma announces the Last Patient, Last Visit in its clinical phase 2b trial with AEF0117 for the treatment of cannabis use disorder

Aelis Farma Strengthens its Leadership Team with the Appointment of Arsène Guekam as Chief Corporate Development Officer